Jeffrey Arcara
Corporate Officer/Principal bij CORVUS PHARMACEUTICALS, INC.
Vermogen: - $ op 31-05-2024
Profiel
Jeffrey S.
Arcara is currently the Chief Business Officer at Corvus Pharmaceuticals, Inc. He previously worked as the Vice President of Business Development at Neuromed Pharmaceuticals Ltd.
He completed his undergraduate degree at the University of Wisconsin and holds an MBA from UCLA Anderson School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 28-02-2024 | 0 ( -.--% ) | - $ | 31-05-2024 |
Actieve functies van Jeffrey Arcara
| Bedrijven | Functie | Begin |
|---|---|---|
| CORVUS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 06-02-2024 |
Eerdere bekende functies van Jeffrey Arcara
| Bedrijven | Functie | Einde |
|---|---|---|
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Corporate Officer/Principal | 27-01-2010 |
Opleiding van Jeffrey Arcara
| University of Wisconsin | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CORVUS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
